Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Hurwitz Website

Arthur Andrew Hurwitz, Ph.D.

Selected Publications

1)  Zhu Z, Singh V, Watkins SK, Bronte V, Shoe JL, Feigenbaum L, Hurwitz AA.
High-avidity T cells are preferentially tolerized in the tumor microenvironment.
Cancer Res. 73: 595-604, 2013.
[Journal]
2)  Watkins SK, Hurwitz AA.
FOXO3: A master switch for regulating tolerance and immunity in dendritic cells.
Oncoimmunology. 1: 252-254, 2012.
[Journal]
3)  Hurwitz AA, Watkins SK.
Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tolerization of T cells.
Cancer Immunol. Immunother. 61: 289-93, 2012.
[Journal]
4)  Watkins SK, Zhu Z, Watkins KE, Hurwitz AA.
Isolation of immune cells from primary tumors.
J Vis Exp. e3952, 2012.
[Journal]
5)  Hudson RS, Yi M, Esposito D, Watkins SK, Hurwitz AA, Yfantis HG, Lee DH, Borin JF, Naslund MJ, Alexander RB, Dorsey TH, Stephens RM, Croce CM, Ambs S.
MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer.
Nucleic Acids Res. 40: 3689-703, 2012.
[Journal]
6)  Hudson RS, Yi M, Esposito D, Glynn SA, Starks AM, Yang Y, Schetter AJ, Watkins SK, Hurwitz AA, Dorsey TH, Stephens RM, Croce CM, Ambs S.
MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer.
Oncogene. [Epub ahead of print], 2012.
[Journal]
7)  Watkins SK, Zhu Z, Riboldi E, Shafer-Weaver KA, Stagliano KE, Sklavos MM, Ambs S, Yagita H, Hurwitz AA.
FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer.
J. Clin. Invest. 121: 1361-72, 2011.
[Journal]
8)  Chen X, Hamano R, Subleski JJ, Hurwitz AA, Howard OM, Oppenheim JJ.
Expression of costimulatory TNFR2 induces resistance of CD4(+)FoxP3(-) conventional T cells to suppression by CD4(+)FoxP3(+) regulatory T Cells.
J. Immunol. 185: 174-82, 2010.
[Journal]
9)  Shafer-Weaver KA, Anderson MJ, Stagliano K, Malyguine A, Greenberg NM, Hurwitz AA.
Cutting Edge: Tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells.
J. Immunol. 183: 4848-52, 2009.
[Journal]
10)  Shafer-Weaver KA, Watkins SK, Anderson MJ, Draper LJ, Malyguine A, Alvord WG, Greenberg NM, Hurwitz AA.
Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells.
Cancer Res. 69: 6256-64, 2009.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 4/11/2013.